Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial
| Autor: | Hugo Roberto Kurtz Lisboa, Leila Beltrami Moreira, Suzi Alves Camey, Patricia Koehler-Santos, Sandra C. Fuchs, Fernanda dos Santos Pereira, Fabiana Piovesan, Glaucia Sarturi Tres |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Blood Glucose Male medicine.medical_specialty Article Subject Endocrinology Diabetes and Metabolism Anti-Inflammatory Agents 030209 endocrinology & metabolism Anthraquinones Type 2 diabetes Placebo lcsh:Diseases of the endocrine glands. Clinical endocrinology law.invention 03 medical and health sciences 0302 clinical medicine Endocrinology Randomized controlled trial Double-Blind Method law Diabetes mellitus Internal medicine Clinical endpoint Medicine Humans Hypoglycemic Agents Diacerein Aged Glycated Hemoglobin Inflammation lcsh:RC648-665 business.industry Middle Aged medicine.disease Clinical trial 030104 developmental biology Treatment Outcome Diabetes Mellitus Type 2 Metabolic control analysis Clinical Study Female business medicine.drug |
| Zdroj: | Journal of Diabetes Research Journal of Diabetes Research, Vol 2018 (2018) |
| ISSN: | 2314-6745 |
| DOI: | 10.1155/2018/4246521 |
| Popis: | Introduction. Studies have shown that T2DM is an inflammatory disease. Thus, the present study was aimed at evaluating whether diacerein could improve the metabolic and inflammatory profile among patients with T2DM under long-term treatment with glucose-lowering agents. Methods. This is a double-blind, parallel, placebo-controlled trial with 72 participants randomly assigned to diacerein 50 mg or placebo for 12 weeks. The primary endpoint was the between-group difference in change in HbA1c. Secondary endpoints included the proportion of patients achieving metabolic control [HbA1c≤7.0% (53 mmol/mol)] and change in inflammatory mediators. Results. Participants in the diacerein group had greater reductions in mean HbA1c level in comparison to placebo (−0.98; 95% CI: −2.02 to 0.05, P=0.06), independently of confounding factors. The difference in HbA1c level was −1.3 (95% CI: −2.3 to −0.4) in favor of diacerein (P=0.007) in those with P=0.9) in those with longer duration. The diacerein group had a 50% increase in the number of participants at the lowest TNF-α level (≤1.46 pg/mL). Conclusions. In patients with long-established T2DM under long-term treatment with glucose-lowering agents, diacerein improves metabolic control as measured by HbA1c level and has a favorable impact on inflammatory profile. Clinical Trial Registry. This trial is registered with Brazilian Clinical Trials Registry (ReBEC) number RBR-29j956. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |